araag2/HINT huggingface dataset:
Clinical trial NCT00143182 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have completed an asenapine 3-week study for the treatment of an acute manic or mixed
             episode and not had a major protocol violation.in the short term study (A7501004 or
             A7501005) that they completed.

        Exclusion Criteria:

          -  Patients with unstable medical conditions or clinically significant laboratory
             abnormalities.
Clinical trial NCT00410384 (phase 3, status: completed)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: placebo, belimumab 1 mg/kg, belimumab 10 mg/kg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Clinical diagnosis of SLE by ACR criteria.

          -  Active SLE disease.

          -  Autoantibody-positive.

          -  On stable SLE treatment regimen.

        Key Exclusion Criteria:

          -  Pregnant or nursing

          -  Have received treatment with any B cell targeted therapy.

          -  Have received treatment with a biological investigational agent in the past year.

          -  Have received IV cyclophosphamide within 180 days of Day 0.

          -  Have severe lupus kidney disease.

          -  Have active central nervous system (CNS) lupus.

          -  Have required management of acute or chronic infections within the past 60 days.

          -  Have current drug or alcohol abuse or dependence.

          -  Have a historically positive test or test positive at screening for HIV, hepatitis B,
             or hepatitis C.
Clinical trial NCT01073865 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: zd9393 (zoladex) 10.8 mg, zd9393 (zoladex) 3.6 mg
SMILES: CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female ≥20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1
             year of randomisation, and 2) E2 ≥10 pg/mL and FSH ≤ 30 mIU/mL within 4 weeks of
             randomisation.

          -  Hormone sensitivity (ER positive) of primary or secondary tumour tissue.

          -  Histological/cytological confirmation of breast cancer and are candidates to receive
             hormonal therapy as therapy for advanced breast cancer.

        Exclusion Criteria:

          -  Patients who have received tamoxifen or other hormonal therapies as adjuvant therapy
             for breast cancer within 24 weeks before randomisation and/or who have received prior
             treatment with hormonal therapies for advanced breast cancer

          -  Patients who have received LHRHa as adjuvant therapy for breast cancer within 48 weeks
             before randomisation

          -  Patients who have relapsed during adjuvant hormonal therapy or within 48 weeks after
             completion of adjuvant hormonal therapy and/or
Clinical trial NCT01214720 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: bevacizumab [avastin]
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  metastatic pancreatic cancer (adenocarcinoma);

          -  good liver, kidney, and bone marrow function.

        Exclusion Criteria:

          -  previous systemic treatment for metastatic pancreatic cancer;

          -  pregnant or lactating females;

          -  fertile men, or women of childbearing potential, not using adequate contraception;

          -  major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start;

          -  current or recent treatment (within 30 days prior to starting study treatment) with
             another investigational drug, or participation in another investigational study.
Clinical trial NCT00573313 (phase 3, status: completed)
Conditions: liver disease, alcoholic
ICD codes: K70.9
Drugs: s-adenosylmethionine, placebo
SMILES: [H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          -  ALD) a history of chronic alcoholism according to established AUDIT and WHO criteria
             with the presence of clinical and laboratory features of established liver disease.
             Also, willingness to undergo liver biopsies at start and completion of the study, and
             to comply with study medication or placebo and required clinic visits and blood
             sampling.

          -  a history of chronic alcoholism without evidence of liver disease;

          -  healthy subjects without history of alcoholism or presence of liver disease.

        Exclusion Criteria:

          -  viral Hepatitis B or C

          -  hemochromatosis

          -  Wilson Disease

          -  sclerosing cholangitis

          -  primary biliary cirrhosis

          -  other chronic disease

          -  renal insufficiency
Clinical trial NCT00658515 (phase 3, status: completed)
Conditions: coronary heart disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: dalcetrapib (ro4607381), evidence-based medical care for acute coronary syndrome, placebo
SMILES: CCC(CC)CC1(CCCCC1)C(=O)NC1=CC=CC=C1SC(=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=45 years of age;

          -  recently hospitalized for ACS;

          -  clinically stable;

          -  receiving evidence-based medical and dietary management of dyslipidemia.

        Exclusion Criteria:

          -  uncontrolled diabetes;

          -  clinically unstable;

          -  severe anemia;

          -  uncontrolled hypertension;

          -  concomitant treatment with any other drug raising HDL-C (eg niacin, fibrates).
Clinical trial NCT01217892 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, dapagliflozin, metformin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Diagnosis of T2DM

          -  Current antihyperglycaemic treatment with metformin immediate release formulation
             monotherapy >/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment.
             Other treatment with OADs within the 10 weeks prior to enrolment is not permitted.

          -  HbA1c ≥ 6.7% and ≤10.5%, based on central laboratory values from Screening Visit, and
             Enrolment Visit 1.

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of
             the Young (MODY) or secondary causes of diabetes mellitus

          -  History of diabetic ketoacidosis

          -  Symptoms of poorly controlled diabetes including, but not limited to, marked polyuria,
             polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment

          -  FPG >270 mg/dL (>15.0 mmol/L)

          -  BMI >45 kg/m2
Clinical trial NCT01449682 (phase 3, status: completed)
Conditions: retinal vein occlusion, macular edema
ICD codes: H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112, H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120
Drugs: ozurdex, ozurdex
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Presence of central retinal vein occlusion (CRVO) or branch retinal vein occlusion
             (BRVO)

          -  Prior treatment with >= 2 intravitreal anti-VEGF injections but no treatment in last
             45 days.

          -  Age 18 years or older

          -  ETDRS Visual acuity between 3 and 72 letters and approximate Snellen equivalent of
             20/25 to 20/800

          -  Central foveal thickness >275 microns or presence of cystic edema on OCT studies.

          -  For sexually active women of childbearing potential, agreement to the use of an
             appropriate form of contraception (or abstinence) for the duration of the study.

          -  Ability to provide written informed consent • Capable of complying with study protocol

        Exclusion Criteria:

          -  History of steroid-related glaucoma (steroid response) requiring more than one topical
             glaucoma medication.

          -  Intraocular injection of steroid medication within prior 4 months

          -  Evidence of significant retinal ischemia on fluorescein angiography in the opinion of
             the treating physician.

          -  Previous laser photocoagulation within 4 months of study

          -  Concurrent ocular disease (e.g proliferative diabetic retinopathy, geographic atrophy)
             that would limit visual acuity in the opinion of the treating physician

          -  Patients who are pregnant.

          -  Unwilling or unable to follow or comply with all study related procedures.
Clinical trial NCT01095835 (phase 3, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: pegylated interferon (peg-ifn) alfa-2a, 180 mcg, pegylated interferon (peg-ifn) alfa-2a, 135 mcg, lamivudine (lam)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adults 18-70 years of age;

          -  HBeAg-negative chronic hepatitis B for >/=6 months;

          -  liver disease consistent with chronic hepatitis B.

        Exclusion Criteria:

          -  interferon-based, systemic anti-HBV, antiviral, anti-neoplastic, or immunomodulatory
             therapy </=12 months before first dose of study drug;

          -  non-responders to previous interferon therapy;

          -  co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV);

          -  hepatocellular cancer;

          -  compensated (Child A, score 6) or decompensated liver disease (Child B or C).
Clinical trial NCT00419757 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol (symbicort) pmdi, budesonide hfa pmdi
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female, Hispanic (self-reported), > 12 years of age

          -  Moderate to severe asthma requiring treatment with an inhaled corticosteroid

          -  Diagnosis of asthma for at least 6 months

        Exclusion Criteria:

          -  Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral,
             ocular)

          -  Any significant disease or disorder that may jeopardize a subject's safety
Clinical trial NCT00689481 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: u0267 foam, vehicle foam
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects at least 12 years old and in good general health.

          -  Mild to moderate plaque-type psoriasis

        Exclusion Criteria:

          -  Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs;
             or to any component of the investigational formulations

          -  History of hypercalcemia or of vitamin D toxicity.

          -  Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis.

          -  Other serious skin disorder or any chronic medical condition that is not well
             controlled.

          -  Use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four
             weeks of enrollment.

          -  Use of topical therapies that have a known beneficial effect on psoriasis, within 2
             weeks of enrollment.

          -  Systemic medications for other medical conditions that are known to affect psoriasis
             within the past four weeks of enrollment.

          -  Use of any investigational therapy within 4 weeks of enrollment.

          -  Pregnant women, women who are breast feeding, or sexually active women of child
             bearing potential who are not practicing an acceptable method of birth control.
Clinical trial NCT00157339 (phase 3, status: completed)
Conditions: diabetes mellitus, asthma, pulmonary disease, chronic obstructive
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40, J44.9, J44.1, J44.0
Drugs: human insulin inhalation powder, injected insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 or type 2 diabetes

          -  asthma or COPD

        Exclusion Criteria:

          -  Current smoking habit
Clinical trial NCT00273507 (phase 3, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin and paclitaxel
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  NSCLC

          -  Stages IB, IIA, IIB, IIIA/T3

          -  Lung function test allowing surgery

          -  Age 18-75 years

        Exclusion Criteria:

          -  Poor lung function

          -  Performance status 3-4

          -  Mediastinal lymph node involvement
Clinical trial NCT00089804 (phase 3, status: terminated)
Conditions: lupus erythematosus, systemic, lupus nephritis
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8, B26.83, A51.44, N11.8, N11.9, N12
Drugs: abetimus sodium (ljp 394) and/or placebo solution, abetimus sodium (ljp 394), phosphate-buffered saline
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    interim efficacy analysis indicated it would be futile to continue study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Systemic Lupus Erythematosus (SLE)

          -  Active SLE renal disease within past 4 years.

          -  Males or females between 12 and 70 years old.

          -  Females must be non-pregnant and non-lactating. Females and males must use adequate
             birth control methods during course of study.

          -  Ability to have weekly intravenous (IV) administration of study treatment.

        Exclusion Criteria:

          -  Active SLE renal disease within past 3 months prior to entering study.

          -  Use of the following therapies within 3 months prior to entering the study: alkylating
             agents, e.g., cyclophosphamide, TNF inhibitors, cyclosporine.

          -  Use of mycophenolate mofetil that exceeds 1000 mg/day, azathioprine that exceeds 100
             mg/day, methotrexate that exceeds 10 mg/week, leflunomide that exceeds 10 mg/day
             within 2 months prior to entering study.

          -  Use of rituximab within 6 months prior to entering study.

          -  Current abuse of drugs or alcohol.
Clinical trial NCT00362934 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: fenofibrate / simvastatin, atorvastatin
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Mixed dyslipidemia.

        Exclusion Criteria:

          -  Known hypersensitivity to fenofibrates or simvastatin or atorvastatin

          -  Pregnant or lactating women

          -  Contra-indication to fenofibrate or simvastatin or atorvastatin

          -  Unstable or severe cardiac disease
Clinical trial NCT00719745 (phase 3, status: completed)
Conditions: liver transplantation
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: prograf, mr4
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients of child bearing potential must have a negative in pregnancy test
             prior to enrollment and must agree to practice effective birth control during the
             study

          -  Patients who need liver transplantation due to the end-stage liver failure

        Exclusion Criteria:

          -  Patients receiving multi-organ transplant or having previously received an organ
             transplant ( including re-transplantation)

          -  Patients receiving auxiliary graft or in whom a bio-artificial

          -  Patients allergic to macrolide antibiotics or tacrolimus

          -  Patients requiring immunosuppressive treatment or systemic chemotherapy prior to
             transplantation. Patients requiring low level immunosuppressive treatment ( MMF,
             steroids, azathioprine ) before transplantation to control their original liver
             disease can be included in the study, provided that this treatment is discontinued at
             the time of transplantation. Local chemotherapy is allowed

          -  Patients with malignancies of a history of malignancy within the last 5 years, with
             the exception of those with basalioma or squamous cell carcinoma of the skin that has
             been treated successfully Patients can be included under Milan Criteria Patients with
             malignancy which was identified after completion of surgery e.g. by histopathology
             will be allowed to remain in the study

          -  Patients with systemic infection requiring treatment, except viral hepatitis

          -  Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal
             disorder that may affect the absorption of tacrolimus

          -  Patients with serum creatinine > 1.5mg/Dl

          -  Patients with any form of substance abuse, psychiatric disorder of condition which, in
             the opinion of the investigator, may complicate communication with the investigator

          -  Patients participating or participated in another clinical trial or those taking or
             having taken an investigational / non-registered drug in the past 28 days

          -  Patients who are pregnant or breast-feeding mother

          -  Patients or donors known to be HIV positive

          -  Patients unlikely to comply with the visits scheduled in the protocol
Clinical trial NCT01318694 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: alisporivir, peginterferon alfa-2a, ribavirin, alv placebo
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Chronic HCV infection

          -  HCV genotype 1

          -  No previous treatment for hepatitis C infection

          -  Serum HCV RNA level ≥ 1000 IU/ml assessed by quantitative polymerase chain reaction or
             equivalent at screening, no upper limit

          -  Liver evaluation prior to baseline: liver biopsy within 3 years or Fibroscan within 6
             months

        Exclusion criteria:

          -  HCV genotype different from genotype 1 or co-infection with other HCV genotype

          -  Co-infection with Hepatitis B or HIV

          -  Any other cause of relevant liver disease other than HCV

          -  Presence or history of hepatic decompensation

          -  Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN), more than 1
             episode of elevated bilirubin (> ULN) in past 6 months

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00235820 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: adalimumab, mtx, placebo adalimumab, placebo mtx
SMILES: O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject was age 18 or older and in good health (Investigator discretion) with a recent
             stable medical history who has had a diagnosis of psoriasis for at least 12 months and
             stable moderate to severe chronic plaque psoriasis

          -  Subject is a candidate for systemic therapy or phototherapy and has active psoriasis
             despite treatment with topical agents.

          -  Subject was able and willing to self-administer sc injections or had available
             qualified person(s) to administer sc injections.

          -  Male subjects must hve been vasectomized or practicing birth control.

        Exclusion Criteria:

          -  Previous systemic anti-TNF therapy.

          -  Prior use of MTX.

          -  Known hypersensitivity to the constituents of adalimumab.

          -  Systemic therapy for psoriasis for at least 4 weeks prior to Baseline; except for
             biologic therapies, which must be discontinued at least 12 weeks prior to enrollment.

          -  Topical psoriasis therapy for at least 2 weeks prior to Baseline, except for
             non-corticosteroid shampoos, bland (no alpha or beta hydroxy) emollients and low
             potency topical corticosteroids on the palms, soles, face, inframammary area, and
             groin only.

          -  Use of tanning beds, excessive sun exposure, or phototherapy (UVB, UVA), for at least
             2 weeks prior to Baseline.

          -  Use of PUVA for at least 4 weeks prior to Baseline.

          -  Use of oral or injectable corticosteroids during the study.

          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate
             for the study.

          -  Female subject who is pregnant or breast feeding or considering becoming pregnant.